313,765 Shares in Foghorn Therapeutics Inc. $FHTX Purchased by Candriam S.C.A.

Posted by Brenda Bartman on Jul 15th, 2026

Candriam S.C.A. bought a new stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX – Free Report) during the first quarter, HoldingsChannel.com reports. The fund bought 313,765 shares of the company’s stock, valued at approximately $1,500,000.

Several other institutional investors have also recently bought and sold shares of FHTX. Raymond James Financial Inc. boosted its position in Foghorn Therapeutics by 4.0% during the 3rd quarter. Raymond James Financial Inc. now owns 2,462,488 shares of the company’s stock worth $12,042,000 after acquiring an additional 95,196 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Foghorn Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,899,457 shares of the company’s stock worth $9,288,000 after acquiring an additional 14,784 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Foghorn Therapeutics by 16.9% in the second quarter. Geode Capital Management LLC now owns 807,674 shares of the company’s stock valued at $3,797,000 after purchasing an additional 116,979 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Foghorn Therapeutics by 151.8% in the fourth quarter. Renaissance Technologies LLC now owns 297,736 shares of the company’s stock valued at $1,608,000 after purchasing an additional 179,500 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Foghorn Therapeutics by 46.2% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 269,186 shares of the company’s stock valued at $1,454,000 after purchasing an additional 85,123 shares during the last quarter. Institutional investors own 61.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on FHTX. Wall Street Zen cut shares of Foghorn Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Foghorn Therapeutics in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.43.

Get Our Latest Stock Report on FHTX

Foghorn Therapeutics Stock Down 1.1%

NASDAQ:FHTX opened at $5.38 on Wednesday. Foghorn Therapeutics Inc. has a twelve month low of $3.27 and a twelve month high of $6.95. The firm has a market capitalization of $315.86 million, a price-to-earnings ratio of -4.64 and a beta of 2.86. The stock’s 50 day moving average price is $4.40 and its two-hundred day moving average price is $5.02.

Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.01). The firm had revenue of $3.27 million during the quarter, compared to the consensus estimate of $7.94 million. As a group, analysts anticipate that Foghorn Therapeutics Inc. will post -0.98 earnings per share for the current year.

About Foghorn Therapeutics

(Free Report)

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.